RESUMEN
Solid tumour cells were shown to express VLA-beta and Thy-1 antigens. For identification of these molecules two monoclonal antibodies, K-20 and ICO-10, characterised in detail previously, were used. Four groups of solid tumours have been identified according to their immunophenotype: VLA-beta+ and Thy-1-; VLA-beta+ and Thy-1+; VLA-beta- and Thy-1+; VLA-beta- and Thy-1-. To a certain extent these groups have been shown to reflect tumour histogenesis: tumours of epithelial origin never expressed an ICO-10+, K20-phenotype while soft tissue sarcomas and neuroblastoma cells never expressed the beta-chain of VLA molecular complexes.
Asunto(s)
Antígenos CD/análisis , Antígenos de Superficie/análisis , Neoplasias/inmunología , Anticuerpos Monoclonales , Humanos , Neoplasias/diagnóstico , Fenotipo , Receptores de Antígeno muy Tardío/inmunología , Antígenos Thy-1RESUMEN
Six hybridoma clones were obtained secreting monoclonal antibodies (Mab) against differentiating antigens of human hemopoietic cells. ICO-1 Mab detect Ia-like (Dr) antigens. Mab react with B-lymphocytes and monocytes without detecting antigens on granulocytes and T-cells. Antigen expression was enhanced following cell activation in a blast cell transformation test and mixed lymphocyte culture (MLC). ICO-1 Mab blocked MLC. The molecular weights of the antigen were 29 and 34 kilodaltons. Comparative studies of ICO-1 Mab with other Mab against Ia-like antigens revealed their identical reactivity. ICO-11 Mab detect the antigen on 4% of blood lymphocytes, 75% thymocytes, monoblasts, and CFU-GM. These Mab block NK-cell activity of blood mononuclear cells. ICO-GM-1 Mab detect the antigen on myelomonocytic cells and their precursors, but not CFU-GM. These Mab block binding of the C3Bi complement component to CR3 receptor and NK-cell activity. ICO-G2 Mab detect the antigen expressed at final stages of granulocyte differentiation. ICO-10 Mab detect the antigen on early thymocytes and ICO-02 on undifferentiated blast cells. Mab were shown to be applicable for human leukemia and lymphoma immune diagnosis.
Asunto(s)
Anticuerpos Monoclonales , Antígenos de Neoplasias/inmunología , Leucemia/inmunología , Linfoma/inmunología , Adulto , Animales , Anticuerpos Monoclonales/biosíntesis , Antígenos de Diferenciación de Linfocitos B/inmunología , Antígenos de Diferenciación de Linfocitos T/inmunología , Niño , Femenino , Granulocitos/inmunología , Humanos , Células Asesinas Naturales/inmunología , Leucocitos Mononucleares/inmunología , Masculino , Ratones , Ratones Endogámicos BALB C , FenotipoRESUMEN
The antiserum was obtained from horses immunized with cells from patients with blastic crisis of CML and completely absorbed with normal white blood cells (WBC). The absorbed antiserum remained cytotoxic to blast cells from nearly half of the patients in blastic crisis and did not react with WBC from patients with Acute Myeloid Leukemia (AML), Acute Lymphoid Leukemia (ALL), Chronic Lymphoid Leukemia (CLL) and Chronic Myeloid Leukemia (CML) in its chronic phase as well as with cells of human normal bone marrow or fetal liver.